The in vitro susceptibility of varicella zoster (VZ) isolates to adenine arabinoside (ara-A) and hypoxanthine arabinoside (ara-Hx) was determined in human skin fibroblasts. Using a system in which deamination was inhibited, and using a modified plaque reduction method, the antiviral activities of ara-A and ara-Hx were separated. The plaque inhibitory concentration of ara-A for all VZ isolates tested was 1 to 2 ,ug/ml and 80 to 100 ,ug/ml for ara-Hx. A comparison of antiviral activity based upon total plaque suppression gave a rate of 40 to 50:1, in favor of ara-A.
In the past several years there has been a growing interest in both the in vitro and in vivo antiviral activity of 9-,3-D-arabinofuranosyladenine (ara-A), a purine nucleoside which is proving to be one of the most promising of the newer antiviral agents. Ara-A has been shown to have inhibitory properties in cellular studies in vitro against large deoxyribonucleic acid viruses, including varicella zoster (VZ) (4, 6, 8, 11) .
Open clinical trials with ara-A in progressive VZ infections in immunosuppressed individuals have been encouraging, especially in those with localized zoster lesions, as reported by Johnson and Luby (6) . In localized infections, relatively low doses of ara-A (5 to 10 mg/kg per day) reportedly resulted in no new vesicle formation after 4 days of therapy. Blinded, placebo-controlled studies underway may provide further evidence of therapeutic efficacy or failure.
Recently, we have described a system for examining viral inhibition in human fibroblastic culture using a quantitative plaque reduction method (1, 3). This method requires that mammalian adenosine deaminase (ADA) generated by tissue culture cells ofthe indicator system or present in mammalian serum be totally inhibited for the test period so that ara-A is not deaminated to hypoxanthine arabinoside (araHx), which has greatly decreased antiviral activity.
Using this system and a quantitative plaque reduction method for VZ, we examined the effect of both ara-A and ara-Hx on plaque development of clinical isolates of VZ virus in human fibroblasts. This report shows that VZ plaque development is inhibited by 1 to 2 ,ug of ara-A per ml and is 40-to 50-fold less susceptible to ara-Hx.
MATERIALS AND METHODS Ara-A and ara-Hx were kindly supplied by Parke, Davis & Co., Detroit, Mich. Ara-Hx was purified by liquid chromatography as previously described by Connor et al. (3) . ADA inhibitor (ADAI) (15) was also supplied by Parke, Davis & Co. in 1 mg/ml aqueous solution.
Plaquing experiments were performed with mycoplasma-free human skin fibroblasts (HSF) derived from newborn foreskin. Growth media consisted of Eagle minimal essential medium with 10% fetal bovine serum, whereas medium with 2% fetal bovine serum was used for all virus-infected cultures. Seven clinical isolates of VZ were collected from chicken pox or herpes-zoster vesicle fluids and subcultured in HSF. Trypsinized suspensions of these infected cells were further subcultured in new HSF until a 75% cytopathogenic effect was observed within 48 h of inoculation.
With some isolates, several passages were necessary in order to harvest cell suspensions with a high proportion of intracellular infection. These infected monolayers were trypsinized and resuspended in growth media and 10% Me2SO (vol/vol). Stock suspensions were then aliquoted and stored in liquid nitrogen at -140 C.
An aliquot from each stock suspension was quick thawed at 37 C and titered as follows. Serial 10-fold dilutions of the infected cell suspensions in maintenance media were added to confluent 30-mm well cultures of HSF in Linbro plates. Plaques developed after 48-to 90-h incubation at 37 C in 5% CO2 and were visualized as described below.
For the susceptibility tests, a cell suspension dilution containing 30 to 60 plaque-forming units/well was used. Each virus strain was tested against concentrations of 3, 2, 1, 0.5, and 0.1 ,ug of ara-A per ml, and four virus strains were tested against 20, 40, 60, 80, and 100 gg of purified ara-Hx per ml as follows.
SUSCEPTIBILITY OF VARICELLA ZOSTER
Growth media was removed from the tissue culture plates, and 2.7 ml of maintenance medium containing various concentrations of ara-A or ara-Hx was added to the appropriate wells. With a micropipette 0.025 ml of a 1:10 dilution of ADAI was added to cultures, followed by 0.3 ml of the appropriate dilution of VZ-infected cell suspension. In the wells used for dilutions of ara-Hx no inhibitor was added. These plates were then incubated at 37 C in 5% CO2 until visible plaque development was evident in the control wells, which varied from 48 to 90 h depending upon the isolate. The wells were stained by adding a few drops of 1% aqueous crystal violet and dried. Plaques were counted under a dissecting microscope at 20 x magnification and appeared as 1-to 2-mm clusters of dark, purple-stained, rounded cells easily distinguishable from the lighter background of the HSF monolayers (Fig. 1) .
Plaque development in triplicate cultures in the presence of ara-A or ara-Hx is expressed as the percentage of the total number of plaques in control cultures containing ADAI alone.
In previous experiments using human diploid fibroblastic cultures with media containing either ara-A or ADAI or both, in comparison to cultures without either compound, after 46 h there were no signs of toxicity as evidenced by microscopic changes, trypan blue staining, neutral red staining, and viability upon subcultivation as determined by ability to form microcolonies and cellular monolayers.
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RESULTS
The effect of ara-A concentration upon plaque development for seven strains of VZ in the presence of deaminase inhibitor is shown in Fig. 2 . Seven VZ isolates were completely inhibited at 2 ug of ara-A per ml (plaque inhibitory concentration, PIC,0), 90% (PICgo) or greater plaque inhibition was observed at 1 gg/ ml, and 50% (PIC50) or greater was at 0.5 ,ugl ml.
There was no difference in antiviral effect of either ara-A or ara-Hx upon VZ strains requiring 48 h for plaque development, in comparison to those requiring 90 h. Antiviral effect was apparent at concentrations as low as 0.1 ,ug/ml. ADAI at the concentration used (0.83 ,ug/ml) had no intrinsic antiviral effect. In HSF monolayers with ADAI the input concentrations of ara-A remained stable for periods up to 9 days, which well exceeded the test period of 48 to 96 h as demonstrated in our laboratory by chromatographic assay (3) . Figure 3 shows the effect of ara-Hx on VZ plaque development. In contrast to ara-A, complete inhibition of plaque development for all four isolates tested was reached at a concentration of 100 ug/ml of ara-Hx, with . tion at 80 pug/ml and >48% at 60 ug/ml. Using the criterion of complete inhibition of plaque development to compare the relative antiviral effect of ara-A and ara-Hx, the ratio of antiviral activity of ara-A to ara-Hx is in the range of 40 to 50:1 for VZ viruses. DISCUSSION This report describes a modified plaque assay for VZ virus and shows that plaque development is susceptible in vitro to ara-A under conditions where deamination of ara-A is prevented and that the antiviral activity of ara-A and ara-Hx can be clearly distinguished using this method.
Since VZ virus is cell-associated in vitro (8) , attempts at studying VZ in tissue culture have been hampered by difficulty in defining reproducibly sensitive quantitative methods for testing antiviral drugs. Several methods for studying VZ virus using infected cells as inocula have been used in the past, including inhibition of cytopathic effects (6, 8) , infective center (4), or plaque development (9, 10).
Rawls and Herrman (10) observed clear plaques with a hand lens when WI-38 monolayers were stained with tetrazolium 7 days after inoculation. Rapp and Benyesh-Melnick (9) observed relatively large 2-to 3-mm clear plaques in 7 to 10 days using neutral red to stain human embryonic lung fibroblastic monolayers inoculated with infective cell suspensions and overlayed with agar. The modified plaque system we used is based upon the original observations of Weller et al. (13, 14) that VZ-infected cells produced characteristic focal areas of rounded cells with intranuclear inclusions which then develop into plaque-like areas in human cell cultures. Further observations of growth of VZ in human fibroblasts (5) confirmed that infective centers slowly enlarge, but remain discreet up to 96 h. Our plaque system produced easily countable, deep purple-staining plaques in 48 to 90 h when stained with 1% aqueous crystal violet without the use of an overlay.
We have previously reported that this human diploid fibroblastic cell line deaminates ara-A with a half-life of 9 h, and addition of ADAI completely prevents deamination (12) .
Previous reports of the in vitro susceptibility of large deoxyribonucleic acid viruses including VZ to ara-A have not taken into account the effect of the indicator system on the drug. VOL. 9, 1976 man embryonic lung fibroblastic monolayers using 1 to 20 ,ug of ara-A per ml and that only two isolates out of 10 tested showed significant reduction in virus yield by 20 -,g of ara-Hx per ml.
The reported inhibitory concentration of ara-A for VZ virus, higher than the values that we have demonstrated, is probably the result of rapid deamination of ara-A during incubation with mammalian cells, thus measuring the effects of either ara-Hx alone or a lower concentration of ara-A than initially incorporated into the tissue culture media. This would depend, of course, on the amount of ADA produced by the cell line, the incubation period, and ADA present in serum used in the medium.
Miller et al. (8) estimated ara-A to be 10 times more active than ara-Hx against herpesvirus, based on a 70% plaque inhibition. This probably does not reflect a true comparison, since the deamination of ara-A was not controlled in the system used. Our data show that a concentration of 80 to 100 ,ug of ara-Hx is necessary to completely inhibit plaque development compared to 2 ,ug of ara-A when ADA is inhibited, thus, making the antiviral ratio of ara-A to ara-Hx from 40 to 50:1. This is similar to the ratio of 50:1 found for herpes simplex virus (3) and vaccinia virus (2) .
Since the major pathway of metabolism of ara-A both in vivo and in vitro is by deamination, it seems important to examine the survival of ara-A in human plasma and tissues, which may vary depending upon the amount of ADA produced by individual tissues. Such information correlated with the in vitro inhibitory concentration might help in developing a logical approach to clinical uses. A. Stuckey, and R. Buchanan. 1974 . Determination of plaque inhibitory activity of adenine arabinoside (9-p-D-arabinofuranosyladenine) for herpesviruses using an adenosine deaminase inhibitor. Antimicrob.
